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The Association between Influenza Treatment and 
Hospitalization-Associated Outcomes among Korean Children 
with Laboratory-Confirmed Influenza
There are limited data evaluating the relationship between influenza treatment and 
hospitalization duration. Our purpose assessed the association between different 
treatments and hospital stay among Korean pediatric influenza patients. Total 770 children 
≤ 15 yr-of-age hospitalized with community-acquired laboratory-confirmed influenza at 
three large urban tertiary care hospitals were identified through a retrospective medical 
chart review. Demographic, clinical, and cost data were extracted and a multivariable 
linear regression model was used to assess the associations between influenza treatment 
types and hospital stay. Overall, there were 81% of the patients hospitalized with 
laboratory-confirmed influenza who received antibiotic monotherapy whereas only 4% of 
the patients received oseltamivir monotherapy. The mean treatment-related charges for 
hospitalizations treated with antibiotics, alone or with oseltamivir, were significantly 
higher than those treated with oseltamivir-only (P < 0.001). Influenza patients treated 
with antibiotics-only and antibiotics/oseltamivir combination therapy showed 44.9% and 
28.2%, respectively, longer duration of hospitalization compared to those treated with 
oseltamivir-only. Patients treated with antibiotics, alone or combined with oseltamivir, 
were associated with longer hospitalization and significantly higher medical charges, 
compared to patients treated with oseltamivir alone. In Korea, there is a need for more 
judicious use of antibiotics, appropriate use of influenza rapid testing.
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INTRODUCTION
Influenza viruses are common respiratory pathogens among 
all age groups and are major causes of excess respiratory dis-
ease-associated hospitalizations, mortality, and costs during 
annual epidemics and pandemics (1, 2). Children with under-
lying medical conditions and younger age, especially ≤ 5 yr 
olds, are at high risk for severe influenza-associated outcomes 
(3-5). Furthermore, pediatric influenza exerts a considerable 
socioeconomic burden in terms of direct and indirect costs, 
and excess health-care utilization (6-8). Children also serve as a 
reservoir for household transmission of influenza, causing sec-
ondary illness in the family (8, 9).
 Currently available neuraminidase inhibitors are effective in 
reducing influenza-associated illness duration, severity, com-
plication risks, influenza-related mortality and even antibiotic 
use (10-12). Often patients hospitalized with influenza-related 
illnesses are inappropriately treated with antibiotics as prophy-
lactic and empiric therapy, as indicated by increased antibiotic 
prescriptions during the influenza season (10, 13). The emer-
gence of drug resistance and over-prescription of antibiotics are 
growing public health issues, as well as increased healthcare 
costs without reductions in illness duration (14-16). 
 Republic of Korea (ROK) has a relatively high influenza vac-
cination coverage rate of nearly 40% in the general population 
(17) and this is higher than the vaccination rate among children 
hospitalized with acute respiratory infection in the US (18) and 
similar to that of healthy Ontario children in Canada (19). None-
theless, Korea still suffers from considerable disease burden of 
influenza in children, where 20% of viral respiratory disease hos-
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pitalizations are due to influenza virus infection (20). This study 
is the first to address treatment patterns in influenza-associated 
hospitalizations among Korean children. To address existing 
gaps in knowledge regarding childhood influenza in Korea, we 
evaluated the association between hospitalization duration and 
treatment type, using clinical and epidemiological data from 
children hospitalized with laboratory-confirmed influenza. We 
also described the economic burden by calculating medical 
charges incurred during hospitalization by treatment type.
MATERIALS AND METHODS
Study hospital and cohort
A retrospective review of medical records for patients admitted 
or treated from February 2004 through June 2007 was conduct-
ed at three academic, tertiary-care hospitals. Ansan, Anam, and 
Guro Hospitals, affiliated with Korea University (KU), serve the 
communities of Ansan city (a neighboring city of Seoul), and 
districts of Anam and Guro in Seoul, respectively. At these KU 
hospitals, nasal aspirate specimens were systematically collect-
ed from patients presenting with acute respiratory symptoms 
and routinely tested to identify adenovirus, parainfluenza, re-
spiratory syncytial virus (RSV) and influenza A/B with virus. 
Additionally, selected patients were tested for influenza A/B 
and RSV by rapid antigen detection (Directigen EZ Flu A+B Test 
Kit, Becton-Dickinson, NJ, USA) at the clinicians’ discretion.
 For this study, we included patients who: a) presented with 
respiratory symptoms at one of the KU hospitals, b) were ≤ 15 
yr-of-age at the time of admission, and c) had laboratory-con-
firmation of influenza A/B. Children with mixed viral infections 
(with following viruses; influenza, RSV, parainfluenza, or ade-
novirus) and with recurrent episodes with the same virus type 
who returned to the hospital within two weeks from the date of 
the previous discharge or clinic visit were excluded from our 
analysis. Assembly of the study patient cohort is outlined in Fig. 
1. During the 41 months, 1,039 episodes of laboratory-confirm-
ed influenza were identified from the outpatient and inpatient 
departments of the three hospitals. 
Virus detection
Viral culture had been performed using an enhanced cell cul-
ture method with fluorescent antibody detection. Specimens 
(200 μL) were inoculated onto R-Mix Ready Cells (Diagnostic 
Hybrids, NY, USA), and vials were centrifuged at 700 × g for 60 
min at room temperature. After overnight incubation at 35°C in 
a CO2 incubator, cell monolayers were washed with phosphate-
buffered saline, fixed with acetone, and stained with a respira-
tory virus fluorescent antibody pool, D3 DFA (Diagnostic Hy-
brids). When virus specific fluorescence was noted, virus iden-
tification was performed by using individual monoclonal anti-
bodies (Diagnostic Hybrids). The presence of three or more cells 
per well with specific apple-green fluorescence was considered 
positive identification. Screenings were done on day 1 and 3. 
Additionally, selected patients were tested for influenza A/B 
and RSV by rapid antigen detection (Directigen EZ Flu A+B Test 
Kit, Becton-Dickinson) at the clinicians’ discretion.
Data collection
Via medical chart reviews of 1,039 episodes of community-ac-
quired laboratory-confirmed influenza, we extracted the fol-
lowing demographic and clinical variables from the KU hospi-
tal electronic medical information database: influenza virus 
Episodes tested for influenza virus among patients ≤15 yr with respiratory symptoms during the study period  
(n = 2,781)




Oseltamivir given within 2 days
(n = 94)
















Lab-confirmed influenza infection episodes  
(n = 1,039)
Non-influenza episodes  
(n = 1,742)
Fig. 1. Flow chart describing the ascertainment of the patient cohort with hospitalization identified during the study period of February 2004-June 2007. 
Lim JK, et al. • Influenza Treatments and Hospitalization Outcomes
http://jkms.org  487http://dx.doi.org/10.3346/jkms.2014.29.4.485
type, dates of admission and discharge, diagnoses, signs and 
symptoms, body temperature, duration of fever, pre-existing 
medical conditions, vital signs, hematologic and radiologic test 
results, treatment information, and discharge status. Direct hos-
pital medical charges were obtained from the hospital billing/
registry office. Treatment-related fee was composed of charges 
for injection, medication, treatment material, physical therapy, 
surgery, anesthesia, and blood infusion. Testing fee consisted of 
charges for routine and specially-ordered laboratory and diag-
nostic tests. Hospital admission fee included admission, food, 
and room charges. They were summed for the total hospital 
charges incurred and currency was converted from Korean Won 
(KRW) to US dollar with the average exchange rate during study 
period of 1 KRW = 0.0007 US$.
 The diagnosis at admission was categorized by the primary 
clinical manifestation. Diagnoses of pneumonia, bronchitis, 
croup, and asthma were grouped as lower respiratory tract ill-
ness (LRTI), while acute pharyngitis, sinusitis, and laryngitis 
were grouped as upper respiratory illness (URI). Urinary tract 
infection, sepsis, and neurologic (e.g., convulsions, febrile sei-
zure, Guillain-Barré Syndrome), gastrointestinal (e.g., diarrhea, 
acute gastroenteritis), and cardiovascular conditions were group-
ed as ‘non-respiratory’ diseases. An axillary (tympanic mem-
brane) temperature ≥ 37.5 (37.8)°C was defined as fever. Fever 
duration included the febrile days prior to admission.
Variable construction and statistical analysis
The analysis examined the relationship between the length of 
hospital stay (LOS) and the different types of treatment admin-
istered during hospitalization, when adjusted for potential con-
founding factors. Nosocomial influenza episodes with virus de-
tection ≥ 7 days after the date of admission were excluded from 
the analysis sample. In accordance with current guidelines of 
influenza treatment, episodes treated with oseltamivir (Tamif-
lu®, Roche Pharmaceuticals, Basel, Switzerland) outside of the 
recommended two-day window after the onset of symptoms, 
and episodes treated with amantadine were excluded. 
 The mean peak body temperature for study patients mea-
sured during hospitalization, 38.6°C, was used as the cutoff val-
ue to create a dichotomous variable indicating elevated body 
temperature. Normal white blood cell (WBC) count was defin-
ed as WBC of 5,000-19,500/µL for children ≤ 10 months-of-age; 
6,000-17,500/µL for those 11 months-2 yr-of-age; 5,500-15,500/
µL for children 3-7 yr-of-age; and 4,500-13,500 (11,500)/µL for 
children 8-13 (14-15) yr-of-age (21). Leukopenia and leukocy-
tosis were below the lower and above the upper values of the 
normal WBC range, respectively. Complications that occurred 
during hospitalization were categorized into secondary bacte-
rial pneumonia, other secondary bacterial infection, encepha-
litis, or exacerbation of the pre-existing medical conditions. Pre-
existing medical conditions were congenital diseases and ac-
quired diseases (e.g., asthma, and cancer). Binary variables were 
created for the presence or absence of complications and pre-
existing conditions.
 Influenza hospitalizations with complete data were divided 
into four treatment categories: oseltamivir-only, antibiotics-on-
ly, antibiotics-plus-oseltamivir, and supportive-care without 
antiviral or antibiotic treatment. Categorical pair-wise compari-
sons were made with reference to the oseltamivir-only group 
using chi-square or the Fisher’s exact tests with significance at 
P < 0.05. Comparison of continuous variables was performed 
using the Student’s t-test. However, for hospital charges with 
skewed distributions, the Mann-Whitney test was used to make 
pair-wise comparisons with reference to the oseltamivir-only 
group. Bivariate analyses were performed to identify potential 
confounders and covariates of interest for the regression model, 
using SAS® version 9.0 (SAS Institute, Cary, NC, USA). 
 To adjust for variability in initial severity of illness, clinical 
parameters such as temperature measured at admission, pre-
senting signs and symptoms (i.e., expectoration, diarrhea, head-
ache, injected tympanic membrane, sore throat, vomiting, brea-
thing difficulty, rales or wheezing), admission diagnosis, labo-
ratory test results (i.e. WBC/neutrophil counts and chest infil-
trates) were compared across treatment groups. Construction 
of the model with these variables allows statistical adjustment 
for initial variability in clinical presentation. As potential con-
founders, presence of underlying medical conditions and oc-
currence of complications during hospitalization, were includ-
ed as dichotomous variables in the model to control for varia-
tions in disease presentation at admission and during clinical 
course that may have guided treatment-related decisions. Some 
variables that are closely related were assessed for multicolline-
arity and were limited for inclusion in the regression model. 
Multivariable linear regression was performed with the out-
come as the log-transformed, hospitalization duration and cat-
egorical variable of influenza treatments as the main predictor. 
The β, % change in treatment-related charges, and 95% confi-
dence intervals (CI) were reported. 
Ethics statement
Study approvals were obtained from the institutional review 
boards of the KU Ansan Hospital (IRB No. ED0744 ) and the In-
ternational Vaccine Institute (IRB No. 2007-008). The exemp-
tion of informed consent and assent forms was allowed by both 
IRBs because this study was based on a retrospective review 




Of the 770 hospitalizations in our analysis sample, 77% were ≤  
Lim JK, et al. • Influenza Treatments and Hospitalization Outcomes
488  http://jkms.org http://dx.doi.org/10.3346/jkms.2014.29.4.485
Table 1. Characteristics of the analysis cohort of hospitalizations with laboratory-confirmed influenza identified during February 2004-June 2007 in Republic of Korea
Treatment group No.
Mean age,  
(yr ± SD)
Female
Influenza virus type Admission diagnosis
A B LRTI URI Non-respiratory
Oseltamivir-only (reference)   27 3.58 ± 3.91 12 (44.4) 13 (48.2) 4 (14.8) 5 (18.5) 12 (44.4) 10 (37.0)
Antibiotics-only 620 3.39 ± 2.76 264 (42.6) 386 (62.3)* 225 (36.3) 354 (57.1)§ 184 (29.7) 82 (13.2)
Antibiotics-plus-oseltamivir   67 3.51 ± 2.90 27 (40.3) 43 (64.2)† 15 (22.4) 28 (41.8)ll 29 (43.3) 10 (14.9)
Supportive-care   56 3.77 ± 3.36 17 (30.4) 36 (64.3)‡ 20 (35.7) 30 (53.6)¶ 15 (26.8) 11 (19.6)
Total 770 3.43 ± 2.86 320 (41.6) 478 (62.1) 264 (34.3) 417 (54.2) 240 (31.2) 113 (14.7)
Values are No. (%) unless otherwise noted. *P < 0.001, for comparison between the antibiotics-only vs oseltamivir-only treatment groups; †P = 0.050, for comparison between 
the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ‡P < 0.001, for comparison between the supportive-care vs oseltamivir-only treatment groups; §P < 0.001, 
for comparison between the antibiotics-only vs oseltamivir-only treatment groups; llP = 0.025, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treat-
ment groups; ¶P = 0.010, for comparison between the supportive-care vs oseltamivir-only treatment groups. LRTI, lower respiratory tract illness; URI, upper respiratory illness.
Fig. 2. Mean length of hospital stay and duration of fever in days for 770 hospitaliza-
tions with laboratory-confirmed influenza by the treatment type, February 2004-June 
2007. *P < 0.001, for comparison of the mean duration of hospital stay in antibiot-
ics-only (5.0 days the oseltamivir-only treatment groups (3.0 days); †P < 0.001, for 
comparison of the mean fever duration in antibiotics-only (5.5 days) vs the oseltami-
vir-only treatment groups (3.8 days); ‡P = 0.012, for comparison of the mean dura-
tion of hospital stay in antibiotics-plus-oseltamivir (4.0 days the oseltamivir-only treat-
























†   
*   
‡   
Hospitalization
Fever
5 yr-of-age (590/770) and there were twice more influenza A 
positive episodes than influenza B episodes (62% vs 34%), with 
few influenza A and B co-infections (Table 1). The distributions 
of hospitalizations by age and gender in the oseltamivir-only 
group were similar to those in other treatment groups. The dis-
tributions of influenza hospitalizations by virus type and ad-
mission diagnosis category were significantly different when 
treatment groups were compared to the oseltamivir-only group. 
The patients in the antibiotics-only, antibiotics-plus-oseltami-
vir, and supportive-care groups were more likely to be diagnos-
ed at admission with LRTI than the oseltamivir-only group (57%, 
42%, and 54% vs 19%, respectively). 
Clinical characteristics
Among the total of 770 patients, 27 were treated with oseltami-
vir-only, 620 were treated with antibiotics-only, 67 received an-
tibiotics-plus-oseltamivir and 56 patients received supportive-
care. The mean LOS for patients in the antibiotics-only and an-
tibiotics-plus-oseltamivir groups were significantly longer com-
pared to the oseltamivir-only group (5.0 and 4.0 vs 3.0 days, re-
spectively) (Fig. 2). The mean fever duration was significantly 
longer in the antibiotics-only group compared to the oseltami-
vir-only group (5.5 vs 3.8 days). Patients in the oseltamivir-only 
group were more likely to have received influenza rapid diag-
nostic tests (IRDT) than the antibiotics-only, antibiotics-plus-
oseltamivir, and supportive-care groups (82% vs 3%, 55%, and 
16%, respectively) (Table 2). Patients who presented with rales/
wheezing were found more commonly in those three treatment 
groups than in the oseltamivir-only group (38%, 37%, and 41% 
vs 7%). Patients presenting with pharyngeal injection were sig-
nificantly less common in the antibiotics-only group, compared 
to the oseltamivir-only group (73% vs 93%). Overall, 12% of pa-
tients (n = 96/770) suffered from complications during hospi-
talization, and 45% (n = 43/96) developed secondary bacterial 
pneumonia or other bacterial infection with few cases of neu-
rologic problems (e.g. encephalitis) and exacerbation of pre-ex-
isting medical conditions (data not shown).
Hospitalization-associated medical charges
The mean treatment-related charges (US$171 and $111 vs $67, 
P < 0.001 and < 0.001, respectively) and the hospital admission 
charges (US$287 and $240 vs $176, P < 0.001 and 0.017, respec-
tively) were significantly higher in the groups treated with anti-
biotics-only and antibiotics-plus-oseltamivir, compared to the 
group treated with oseltamivir-only (Table 3). The mean total 
charges for hospitalizations treated with antibiotics-only and 
antibiotics-plus-oseltamivir were significantly higher than charg-
es for hospitalizations treated with oseltamivir-only (US$753 and 
$623 vs $508, P < 0.001 and 0.059, respectively). 
Predictors of increased hospital stay
Compared with the oseltamivir-only group, children treated 
with antibiotics-only showed 44.9% longer hospitalization com-
pared to those who received oseltamivir-only (95% CI, 15.85- 
81.33; P value = 0.001) (Table 4) in multivariate analysis. Treat-
ment with antibiotics-plus-oseltamivir also showed a signifi-
cantly longer LOS, compared to the oseltamivir-only group, by 
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28.2% (95% CI, 1.96-61.11; P value = 0.034). From the univariate 
analysis, patients who received the antibiotics-only therapy show-
ed 55.8% longer hospitalization compared to those who received 
oseltamivir-only (95% CI, 27.99-89.66; P value < 0.001) (data not 
shown). Patients who received antibiotics-plus-oseltamivir ther-
apy also showed a significantly longer LOS by 28.5%, compared 
to the oseltamivir-only group (95% CI, 2.24-61.48; P value = 0.032). 
 Children in the 3-5 yr-old groups showed to have 12.6% shor-
ter LOS, compared to infants ≤ 1 yr old (95% CI, -21.9~-2.18; P 
value = 0.019). Patients with dyspnea had 18.0% longer LOS 
compared to those without dyspnea (95% CI, 0.28-38.86; P val-
ue = 0.046), while those children with admission diagnosis cat-
egorized as URI showed 9.3% shorter LOS compared to those 
with LRTI (95% CI, -17.52~-0.29; P value = 0.044). Also, the pres-
ence of chest radiograph infiltrates and pre-existing medical 
conditions were significant indicators of lengthened hospital-
ization by 12.9% and 21.3%, respectively (95% CI, 3.50-23.04 and 
6.27-38.32, respectively). 
Table 2. Clinical characteristics of the 770 hospitalizations with laboratory-confirmed influenza treated with antiviral or antibiotic medication from February 2004 to June 2007
Characteristics
Treatment
Oseltamivir-only (reference) Antibiotics-only Antibiotics plus oseltamivir Supportive-care
Temperature at admission (°C) mean (SD) 37.65 (0.85) 37.54 (0.98) 37.79 (0.89) 37.25 (0.80)
Peak temperature during hospitalization (°C) mean (SD) 38.50 (0.69) 38.61 (0.86) 38.87 (0.89) 38.13 (0.99)










































































Neutrophil (ref. normal, 54%-62%)
Outside normal range 26 (96.3) 541 (87.3) 59 (88.1) 49 (87.5)
Chest radiograph infiltrates 5 (18.5) 194 (31.3) 10 (14.9) 17 (30.4)
Presence of complications 3 (11.1) 80 (12.9) 4 (6.0) 9 (16.1)
Presence of underlying diseases 1 (3.7) 53 (8.6) 5 (7.5) 7 (12.5)
Values are No. (%) unless otherwise noted. The 95% confidence intervals (95% CI) were reported. *P < 0.001, for comparison between the antibiotics-only vs oseltamivir-only 
treatment groups; †P = 0.017, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ‡P < 0.001, for comparison between the supportive-
care vs oseltamivir-only treatment groups; §P = 0.022, for comparison between the antibiotics-only vs oseltamivir-only treatment groups; llP = 0.001, for comparison between 
the antibiotics-only vs oseltamivir-only treatment groups; ¶P = 0.004, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; **P = 0.002, 
for comparison between the supportive-care vs oseltamivir-only treatment groups; ††P = 0.002, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treat-
ment groups; ‡‡P = 0.002, for comparison between the supportive-care vs oseltamivir-only treatment groups; §§P = 0.011, for comparison between the antibiotics-only vs osel-
tamivir-only treatment groups; ll llP = 0.049, for comparison between the antibiotics-plus-oseltamivir vs oseltamivir-only treatment groups; ¶¶P = 0.010, for comparison between 
the supportive-care vs oseltamivir-only treatment group.
Table 3. Hospital charges (mean, SD) of patients with laboratory-confirmed influenza by treatment type, February 2004-June 2007
Type of hospital charge 
Treatment type
Oseltamivir-only (reference) Antibiotics-only Antibiotics plus oseltamivir Supportive-care
Treatment-related 66.55 (37.39) 170.67 (713.34)* 110.98 (60.28)† 78.41 (77.69)
Hospital admission 175.76 (92.45) 287.16 (335.04)‡ 240.23 (158.49)§ 212.60 (112.64)
Testing 230.35 (156.88) 238.76 (193.89) 226.88 (138.77) 227.25 (167.84)
Total 507.82 (208.36) 753.47 (1247.68)ll   623.18 (283.89) 556.58 (248.91)
Mean values and standard deviation (in parenthesis) are reported in US$ with exchange rate of 1 KRW = 0.0007 US$. *P < 0.001, for comparison of the mean treatment-re-
lated fees in antibiotics-only vs the oseltamivir-only treatment groups; †P < 0.001, for comparison of the mean treatment-related fees in antibiotics-plus-oseltamivir vs the os-
eltamivir-only treatment groups; ‡P < 0.001, for comparison of the mean hospital admission charges in antibiotics-only vs the oseltamivir-only treatment groups; §P = 0.017, 
for comparison of the mean hospital admission charges in antibiotics-plus-oseltamivir vs the oseltamivir-only treatment groups; llP < 0.001, for comparison of total hospital char-
ges in antibiotics-only vs the oseltamivir-only treatment groups.
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DISCUSSION
This is the fir st study to compare influenza treatments in rela-
tion to hospitalization-associated outcomes among Korean 
children. Our findings suggest that antibiotic therapy, alone or 
in combination with oselatmivir, is associated with longer hos-
pitalization, compared to oseltamivir monotherapy, among 
children with laboratory-confirmed influenza. Also, our data 
showed that the lowest mean total hospital charges, as well as 
hospital admission and treatment-related charges, occurred 
among patients treated with oseltamivir-only among different 
influenza treatment options. In our sample of influenza hospi-
talizations, 81% of patients received antibiotic-only while only 
4% received oseltamivir-only. Patients who received oseltamivir 
monotherapy were more likely to be laboratory-confirmed with 
IRDT in addition to culture tests than patients who received 
other treatments. 
 Our results are consistent with findings from Kaiser et al. and 
Gums et al. that demonstrated the effectiveness of oseltamivir 
in reducing the length of hospitalization (10, 22); and Sato, et al. 
that showed a significantly shorter duration of fever in oselta-
mivir-treated influenza A patients (12). Our data showed a sig-
nificantly longer mean LOS for patients in the antibiotics-only 
and antibiotics-plus-oseltamivir groups compared to the osel-
tamivir-only group. Less timely onset of antibiotic therapy could 
play a role in increased LOS, however, 99% (n = 683) of 687 an-
tibiotics-treated patients received antibiotics within 3 days of 
admission in our data, indicating the timing of antibiotic thera-
py was unlikely the cause of observed association. In the antibi-
otics-plus-oseltamivir group, 59 patients out of 67 had received 
antibiotics before oseltamivir in our data. While this may be ex-
plained by the fact that these patients may have had clinical in-
dications of bacterial pneumonia or other secondary infections, 
this antibiotic prescription preceding oseltamivir treatment 
could have led to delayed onset of oseltamivir therapy and con-
sequently lengthening the patients’ LOS.
 Several factors, indicating severe clinical course (e.g., compli-
cation) and initial differences in clinical presentation of illness, 
Table 4. Multivariate regression analysis of association between treatment type received and hospitalization duration among 770 hospitalizations with laboratory-confirmed in-
fluenza in Republic of Korea, February 2004 through June 2007
Characteristics B* (% change in hospitalization duration) 95% Confidence Interval (% change) P value


























Antigen detection test performed (ref. no)
Yes -0.044 (-4.33) -0.196-0.107 (-17.79-11.32) 0.566
Clinical attributes at admission
Body temperature (ref. < 38.6°C)
≥ 38.6°C 
Unavailable
Presence of signs and symptoms (ref. absent)











White blood cell count (ref. normal count)
Leucopenia
Leukocytosis
Neutrophil (ref. normal, 54%-62%)
Neutropenia
Neutrocytosis
Chest radiograph infiltrates (ref. absence)























































Presence of complications (ref. absence) -0.026 (-2.57) -0.141-0.089 (-13.13-9.27) 0.656
Note. ref denotes reference for each categorical variable. *In addition to the variables listed in the table, the multivariate analysis was adjusted for sex, influenza season, pres-
ence of signs/symptoms (chills, rales/wheezing, cough, expectoration, rhinorrhea, diarrhea, sore throat, pharyngeal injection, rhonchi, and headache).
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could have potentially influenced treatment-related decisions 
and were taken into account in our multivariate modeling. It is 
possible that additional confounding variables that were not 
measured in this study may explain the relationship. However, 
the observed strength of the relationship of oseltamivir-only 
compared to antibiotics-only and antibiotics-plus-oseltamivir 
groups (i.e., 45% and 28% increases in LOS with the P value of 
0.001 and 0.034, respectively) makes it unlikely that our find-
ings are a result of residual confounding not controlled for in 
our models. While these findings are consistent with several re-
ports of reduced hospitalization associated with oseltamivir 
treatment (10, 22), no previous studies have shown that antibi-
otic treatments, compared to oseltamivir therapy, is associated 
with longer LOS in children with laboratory-confirmed influ-
enza.
 Our finding that hospital charges were lowest among oselta-
mivir-only treated children also corresponds with previous stu-
dies reporting that unnecessary costs may incur among influ-
enza-like illness (ILI) patients treated with antibiotics (13, 16, 
23) while oseltamivir is the cost-effective choice of influenza 
treatment (24). The cost of influenza-related hospitalization in 
our data was shown to be lower than previously estimated in 
other countries (6, 7, 25). This is explained by the fact that ROK 
has universal population coverage by the National Health In-
surance that subsidizes physician fees, hospital and prescrip-
tion drugs charges via a compulsory healthcare plan (26). De-
spite the number of studies that have previously reported an in-
discriminant and inappropriate use of antibiotics (16, 27, 28), 
antibiotics were demonstrated to still be a primary treatment 
option for children hospitalized with influenza in ROK. Observ-
ed treatment patterns may be explained, in part, by the absence 
of standardized treatment guidelines for seasonal influenza in 
ROK.
 In addition to the absence of the treatment guidelines, infre-
quent use of the IRDT during the study period could lead to ob-
served treatment patterns. Without test for viral pathogen, the 
uncertainty of diagnosis of children with influenza-like illness 
frequently leads clinicians to prescribe antibiotics to the chil-
dren with lower respiratory symptoms and signs. Our data show-
ed that the oseltamivir-treated children were more likely to have 
been tested with IRDT compared to the children treated with 
antibiotics or supportive-care. Although all of our study sub-
jects were ultimately proven to have laboratory-confirmed in-
fluenza, children who were treated with antibiotics or only sup-
portive-care may have been initially suspected of having bacte-
rial infection or non-viral respiratory illness. Such children were 
less likely to undergo testing by IRDT than those oseltamivir-
treated, who were more likely to be confirmed with influenza 
on admission with IRDT. Our results as well as previous studies 
support the notion that IRDT are an important tool for guiding 
influenza treatment decision-making (29, 30). Distinguishing 
influenza from other respiratory diseases in children as well as 
identifying influenza with atypical clinical presentations is a 
well-recognized clinical challenge (31). As a result, increased 
accessibility of IRDT is a recognized priority among clinicians 
in ROK and elsewhere that is likely to improve patient treatment 
regimens and clinical outcomes, as well as potentially reduce 
antibiotic usage and additional laboratory testing (29, 30, 32). 
 In our study, we adjusted for clinical characteristics in our 
multivariable analysis that were previously linked to higher in-
fluenza viral load, prolonged hospitalization, secondary pneu-
monia, as well as other viral or bacterial complications (33-38). 
We found no consistent treatment-related patterns with respect 
to disease severity of illness when compared clinical presenta-
tion by treatment type. For example, rales/wheezing were more 
commonly present among patients treated with antibiotics-on-
ly, antibiotics-plus-oseltamivir, and even supportive-care, com-
pared to those treated with oseltamivir-only, Also, chest infil-
trate, which may suggest bacterial pneumonia (39), was not 
significantly more common in antibiotics or antibiotics-plus-
oseltamivir groups compared to the oseltamivir-only group. 
There was no currently available and validated severity of ill-
ness index for pediatric influenza.
 In this retrospective study, our data extraction was limited to 
the information available on medical charts. Due to the obser-
vational nature of our study, we cannot conclude that oseltami-
vir shortened the LOS among hospitalized patients with influ-
enza. Although lengthened hospitalization practically directly 
reflects the burden of influenza requiring hospitalization, clini-
cal data may not entirely capture the influenza disease burden. 
In clinical practice at KU hospitals, the hospitalizations diag-
nosed with mild conditions (e.g., pharyngitis) were less likely to 
be treated with antibiotics, while those with more severe find-
ings, such as rales or chest infiltrate that prompt clinicians to 
suspect bacterial pneumonia, were often treated with antibiot-
ics. Thus, variability in illness severity at admission influencing 
clinical diagnosis was the most important confounder of this 
relationship and various clinical attributes were controlled for 
in the analysis. 
 Despite these limitations, a robust analysis of the treatment 
type was possible due to: 1) three complete and consecutive vi-
ral seasons; 2) a relatively large sample of laboratory-confirmed 
influenza hospitalizations; 3) the geographic and patient mix of 
patients from community and academic hospitals in different 
parts of ROK, providing a representative sample for greater ge-
neralizability of results; and 4) no oseltamivir resistance in the 
viral strains during our study period in ROK (anecdotal reports), 
minimizing the influence of oseltamivir resistance on the study 
outcomes. Prescription patterns could differ by clinician and 
facility, but the three hospitals under the umbrella of KU had 
highly uniform standards in patient management and treatment 
regimen. Moreover, all subjects were culture-confirmed, in ad-
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dition to some that had undergone IRDT, ensuring uniformity 
in the levels of sensitivity and specificity of influenza diagnos-
tics. Considering the lack of data from direct comparison be-
tween antibiotic and oseltamivir treatments, our study provides 
a realistic illustration of influenza treatment in relation to in-
creased hospitalization by comparing treatment options used 
in clinical practice in ROK. As suggested by Falagas et al., there 
is a need for comparative and randomized studies (40), our study 
findings will serve as a platform for further assessment of differ-
ent influenza treatment options in clinical practice.
 In ROK, the predominantly circulating strains were A/H3N2 
in 2004-05, A/H1N1 in 2005-06, and A/H3N2 in 2006-07 and 
there were no reported oseltamivir-resistant strains of influenza 
during the study period of 2004-07. Notably, in the January 2011 
issue of the U.S. Centers for Disease Control and Prevention’s 
Morbidity and Mortality Weekly Report, either oseltamivir or 
zanamivir was recommended for use in patients hospitalized 
with suspected or confirmed influenza, whether it is 2009 H1N1 
virus, influenza A (H3N2) virus, or influenza B virus or when 
the influenza virus type or influenza A virus subtype is unknown 
(41). In ROK, there is limited number of oseltamivir treatment 
guidelines or recommendations for seasonal influenza. Also, 
IRDT is not routinely used in decision-makings of patient man-
agement, despite its well-known benefits (23, 32, 37). Lately, 
real time RT-PCR is used more often in many facilities in ROK, 
which means influenza infection could be detected in earlier 
stage of illness with better accuracy.
 Recognizing that laboratory-confirmation of influenza at an 
earlier point of the course of hospitalization may be particularly 
important in pediatric influenza treatment (29, 42), our study 
suggests the need for appropriate use of IRDT and RT-PCR for 
seasonal influenza in ROK so that more vigilant and judicious 
antibiotics prescription could be practiced in the clinical setting. 
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